Oncolytics Biotech Inc., of Calgary, Alberta, said it plans to report updated results during the International Association for the Study of Lung Cancer 16th World Conference on Lung Cancer in Denver next monhth, including longer-term survival data, from the company's REO 016 phase II study of Reolysin (pelareorep) given intravenously with paclitaxel and carboplatin every three weeks for the treatment of non-small-cell lung cancer.